<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053543</url>
  </required_header>
  <id_info>
    <org_study_id>CXA-10-2302</org_study_id>
    <nct_id>NCT04053543</nct_id>
  </id_info>
  <brief_title>CXA-10 Study in Subjects With Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Analytics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Complexa, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate&#xD;
      the long term safety and efficacy of daily dosing of CXA-10.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate&#xD;
      the long term safety and efficacy of daily dosing of CXA-10.&#xD;
&#xD;
      The study will be performed in approximately 50 study centers across the United States and&#xD;
      the United Kingdom, which participated in CXA-10-301. Approximately 96 subjects who completed&#xD;
      treatment in CXA-10-301 will be eligible to participate in this OLE study, after completing&#xD;
      all Visit 9 (Day 1 and Day 2) assessments in CXA-10-301.&#xD;
&#xD;
      Study participation for each subject will last up to approximately 6.5 months. The study will&#xD;
      consist of a 6 month open-label treatment period and require 5 clinic visits and 1 telephone&#xD;
      visit, including the Baseline Visit completed simultaneously with Visit 9 CXA-10-301, plus a&#xD;
      follow-up visit approximately 2 weeks following the last dose of CXA-10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    LOE&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CXA-10</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events occurring during the treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in respiration</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline values at each post-baseline time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline values at each post-baseline time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline values at each post-baseline time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PAH-specific medication changes</measure>
    <time_frame>6 months</time_frame>
    <description>Addition or removal of PAH-specific medications, including any dose changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Distance</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in 6-minute walk distance (6MWD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Who Classification of Functional Status</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in WHO Classification of Functional Status of Patients with PH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>6 months</time_frame>
    <description>Death from any cause, hospitalization for worsening PAH, Disease progression, unsatisfactory long-term clinical response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>PAH</condition>
  <arm_group>
    <arm_group_label>150mg CXA-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dosing of 150mg CXA-10 in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXA-10</intervention_name>
    <description>(10-nitro-9(E)-octadec-9enoic acid)</description>
    <arm_group_label>150mg CXA-10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating subject&#xD;
             has been informed of all pertinent aspects of the study prior to initiation of any&#xD;
             study-required procedures.&#xD;
&#xD;
          2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests&#xD;
             and other study procedures.&#xD;
&#xD;
          3. Has completed the CXA-10-301 study and demonstrated compliance with study medication&#xD;
             administration and study requirements.&#xD;
&#xD;
          4. If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any&#xD;
             other combination therapy containing simvastatin, simvastatin dose does not exceed 20&#xD;
             mg/day.&#xD;
&#xD;
          5. Currently receiving no more than three of the following previously approved PAH&#xD;
             therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor&#xD;
             antagonists (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids,&#xD;
             prostacyclin receptor agonists.&#xD;
&#xD;
          6. Women of childbearing potential and males with partners of childbearing potential must&#xD;
             agree to use a reliable method of contraception while taking study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hypotension defined by systolic blood pressure &lt;90 mmHg from sitting blood&#xD;
             pressure measurement at Baseline.&#xD;
&#xD;
          2. Hypertensive defined by &gt;160 mmHg systolic or &gt;110 mmHg diastolic from sitting blood&#xD;
             pressure measurement at Baseline.&#xD;
&#xD;
          3. QTcF on supine ECGs at Baseline (Visit 1) of &gt;500 msec.&#xD;
&#xD;
          4. Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial&#xD;
             Infarction [STEMI], Non STEMI [NSTEMI] and or unstable angina) within the last 90 days&#xD;
             prior to Baseline.&#xD;
&#xD;
          5. Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90&#xD;
             days prior to Baseline.&#xD;
&#xD;
          6. Recent hospitalization for left heart failure within the last 90 days prior to&#xD;
             Baseline.&#xD;
&#xD;
          7. Clinically significant aortic or mitral valve disease defined as greater than mild&#xD;
             regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive&#xD;
             cardiomyopathy; left ventricular dysfunction (LVEF &lt; 50%); left ventricular outflow&#xD;
             obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid&#xD;
             depletion, in the opinion of the investigator.&#xD;
&#xD;
          8. Chronic atrial fibrillation and life-threatening cardiac arrhythmias.&#xD;
&#xD;
          9. Personal or family history of congenital prolonged QTc syndrome or sudden unexpected&#xD;
             death due to a cardiac reason.&#xD;
&#xD;
         10. Clinically significant anemia in the opinion of the investigator that precludes&#xD;
             enrollment into this study, or Hb &lt;9 gm/dl.&#xD;
&#xD;
         11. Severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at Baseline&#xD;
             or active chronic hepatitis.&#xD;
&#xD;
         12. Received intravenous inotropes within 2 weeks prior to Baseline (e.g. dopamine,&#xD;
             dobutamine).&#xD;
&#xD;
         13. History of angina pectoris or other condition that was treated with long or short&#xD;
             acting nitrates &lt;12 weeks of Baseline.&#xD;
&#xD;
         14. History of herbal or natural medication use (including fish oil) within 2 weeks or 5&#xD;
             half-lives, whichever is longer, prior to Baseline.&#xD;
&#xD;
         15. Received prednisone at doses &gt; 15 mg/ day or changes in immunosuppressive medications&#xD;
             &lt;12 weeks prior to Baseline.&#xD;
&#xD;
         16. Currently taking a drug that may affect the assay measurement of serum creatinine&#xD;
             (e.g. cimetidine, Bactrim, Pyridium). A list is provided in Appendix H.&#xD;
&#xD;
        21. Newly prescribed drug or increased dose of an existing drug that is known to prolong&#xD;
        the QTc interval and has been associated with Torsades de Pointes (TdP) identified in the&#xD;
        CredibleMeds.org website list as known risk (KR) of TdP.&#xD;
&#xD;
        Note: Stable doses of drugs classified as conditional risk (CR) of TdP or possible risk&#xD;
        (PR) of TdP are permitted (i.e., subject has received the same dose and regimen for at&#xD;
        least 30 days prior to Baseline with no anticipated changes to the dose or regimen during&#xD;
        the course of the study).&#xD;
&#xD;
        22. Currently taking dimethyl fumarate (Tecfideraâ„¢).&#xD;
&#xD;
        23. Any of the following laboratories abnormal and unresolved in CXA-10-301:&#xD;
&#xD;
          1. Absolute lymphocyte counts &lt; 0.5 x 109 cells/L.&#xD;
&#xD;
          2. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 3.0X upper&#xD;
             limit of normal (ULN), alkaline phosphatase (AP) &gt; 2X ULN of liver origin, and total&#xD;
             bilirubin &gt;2X ULN. If all liver function tests (LFTs) are within normal limits (WNL)&#xD;
             and total bilirubin is elevated, examination of direct and indirect bilirubin may be&#xD;
             conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's&#xD;
             Syndrome may be enrolled.&#xD;
&#xD;
          3. eGFR &lt; 30 mL/min/1.73 m2 (estimated by Chronic Kidney Disease Epidemiology&#xD;
             Collaboration [CKD-EPI] Creatinine/Cystatin C 2012 algorithm) at Baseline.&#xD;
&#xD;
             24. Females who are pregnant or breastfeeding, or who are trying to conceive. 25.&#xD;
             Recent (within 1 year) history of abusing alcohol or illicit drugs. 26. History of any&#xD;
             primary malignancy, including a history of melanoma or suspicious undiagnosed skin&#xD;
             lesions, or other malignancies (such as thyroid or testicular) that have been&#xD;
             curatively treated and with no evidence of disease for at least 3 years or prostate&#xD;
             cancer who is not currently or expected, during the study, to undergo radiation&#xD;
             therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal&#xD;
             treatment.&#xD;
&#xD;
             Exception: subjects with history of basal cell or squamous cell carcinomas of the skin&#xD;
             or cervical carcinoma in situ are eligible for enrollment.&#xD;
&#xD;
             27. Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic,&#xD;
             endocrine, metabolic, central nervous system or psychiatric disease that, in the&#xD;
             opinion of the investigator, may adversely affect the safety of the subject and/or&#xD;
             efficacy of the investigational product or severely limit the lifespan of the subject&#xD;
             other than the condition being studied.&#xD;
&#xD;
             28. Clinically significant hyperthyroidism or hypothyroidism not adequately treated.&#xD;
&#xD;
             29. Any other condition and/or situation that causes the Investigator to deem a&#xD;
             subject unsuitable for the study (e.g., due to expected study medication non-&#xD;
             compliance, inability to medically tolerate the study procedures, or a subject's&#xD;
             unwillingness to comply with study-related procedures).&#xD;
&#xD;
             30. Known hypersensitivity to CXA-10, the metabolites, or formulation excipients.&#xD;
&#xD;
             31. Treatment with any investigational drug (other than CXA-10) or device within 30&#xD;
             days or 5 half-lives (whichever is longer) prior to Baseline (this includes&#xD;
             investigational formulations of marketed products, inhaled and topical drugs), or&#xD;
             plans to participate in an investigational drug or device study at any time during&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Danoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Complexa, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital (Medstar)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesotta</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University and Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10279</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Hospital-Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbuilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedert Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Connective Tissue Disease- Associated</keyword>
  <keyword>6 Minute Walk Test</keyword>
  <keyword>6 Minute Walk Distance</keyword>
  <keyword>Pulmonary Vascular Resistance</keyword>
  <keyword>Cardiac MRI</keyword>
  <keyword>Right Ventricular Function</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Familial Primary Pulmonary Hypertension</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Hypertension, Pulmonary</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CXA-10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

